Patents by Inventor Abolgasem Baghian

Abolgasem Baghian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccines for infections
    Patent number: 7279171
    Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.
    Type: Grant
    Filed: August 11, 2003
    Date of Patent: October 9, 2007
    Assignee: Board of Supervisors of Louisiana State University and Mechanical College
    Inventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
  • Vaccines for Chlamydia psittaci infections
    Publication number: 20050037019
    Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.
    Type: Application
    Filed: August 11, 2003
    Publication date: February 17, 2005
    Inventors: Konstantin Kousoulas, Vladimir Chouljenko, Abolgasem Baghian, Thomas Tully
  • Vaccines for Chlamydia psittaci infections
    Patent number: 6605287
    Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 12, 2003
    Assignee: Board of Supervisors of Louisiana State University & Agricultural and Mechanical College
    Inventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
  • VACCINES FOR CHLAMYDIA PSITTACI INFECTIONS
    Publication number: 20020136742
    Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.
    Type: Application
    Filed: August 28, 1998
    Publication date: September 26, 2002
    Inventors: KONSTANTIN G. KOUSOULAS, VLADIMIR N. CHOULJENKO, ABOLGASEM BAGHIAN, THOMAS N. TULLY, JR.